SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Charts With An Attitude; Trading In & Out -- Ignore unavailable to you. Want to Upgrade?


To: OldHack who wrote (4283)12/10/1997 6:44:00 AM
From: Linda Kaplan  Respond to of 4701
 
OH,

You were really smart to use the stop loss on VVUS, though! The physicians in the VVUS thread claim the competing drug doesn't do the same thing and won't help most of the population that VVUS will help. But the perception of the marketplace is that the competing drug is superior, because the delivery system is superior. The competing drug isn't even approved, so it could be a long time before the people saying that VVUS sales will be enhanced by the competing product will have proof of their claims.

I decided to AIM VVUS, which turns it into a long term investment, and that could have been a mistake, since it's done nothing but go down. I have been successful in such situations with out-of-favor stocks in the past, however. It requires patience and capital, because you have to keep averaging down. I don't have much patience, but I can pretend, and I don't have much capital -- but I keep hoping I'll be able to liberate more soon.

The really worst thing about VVUS for me is that I sunk a lot of money into December calls and I'm going to lose all of that money. That has been making me sick. I think I'll be much more careful about buying options in the future.

Let me know what your research uncovers and also if you find something good for refinishing. What's an MJ? It sounds like I need one.

Linda



To: OldHack who wrote (4283)12/10/1997 8:18:00 AM
From: Mark  Respond to of 4701
 
Today's Wall Street Journal had a couple of articles on ORCL. Not very positive. Insider trading, all sells. Another was about the prospects for a return to the previous growth rate of 35%. Not likely for at least 2 more quarters.

Read the hard copy. Articles in section A and section C. Looks like a hold here. New money should wait for a bit of a settlement. Still too volitle.

Just my $.02.

Mark